FDA Reviews Decision on Moderna's mRNA Flu Vaccine

The FDA has reversed its decision and begun reviewing Moderna's mRNA flu vaccine, after an earlier and surprising refusal.

FDA Reviews Decision on Moderna's mRNA Flu Vaccine
FDA logo with an mRNA flu vaccine background

The U.S. Food and Drug Administration (FDA) has recently changed course, deciding to begin reviewing Moderna's mRNA flu vaccine, mRNA-1010. The decision follows an initial refusal that had raised concerns about the Trump administration's approach to vaccine development.

The Initial Refusal and the Controversy

On February 3, 2026, the FDA issued a "Refusal-to-File" (RTF) letter for Moderna's application, citing the lack of an "adequate and well-controlled" study. In particular, the agency criticized Moderna's choice of a standard-dose flu vaccine as the comparator, arguing it was not representative of the best available standard of care. This raised doubts about the validity of the clinical trial, which involved about 41,000 adults aged 50 and older.

Moderna's Response and the FDA's Review

In response to the refusal, Moderna requested a formal meeting with the FDA, known as a "Type A meeting", to discuss the concerns raised. During the meeting, the company proposed changing the regulatory pathway, seeking full approval for adults aged 50 to 64 and accelerated approval for adults 65 and older, with a commitment to conduct an additional post-marketing study in that age group. The FDA accepted this proposal and began reviewing the vaccine, with a target decision date set for August 5, 2026.

Implications for Health Policy and Vaccine Development

This episode has highlighted the tensions between the scientific community and political influences in vaccine regulation. The initial refusal by the FDA, followed by the subsequent review, has raised questions about the role of political considerations in scientific decisions. The situation has also highlighted the challenges of developing innovative vaccines, such as those based on mRNA technology, and the importance of ensuring that health policy is guided by solid scientific evidence.

Future Outlook

With the review underway, the health sector is watching closely for the outcome of the evaluation of Moderna's mRNA-1010 vaccine. If approved, this vaccine could represent a significant advance in flu prevention, offering a new option to protect the population, particularly older adults, against complications associated with seasonal flu.

  • The FDA's initial refusal: The FDA first rejected Moderna's application for mRNA-1010, citing concerns about the clinical study and the choice of comparator.
  • A change in regulatory pathway: Moderna proposed a revised regulatory pathway, seeking separate approvals for different age groups and committing to additional studies.
  • Review underway: The FDA accepted Moderna's proposal and began reviewing the vaccine, with a target decision date of August 5, 2026.
  • Policy implications: The situation has raised questions about the role of political influence in scientific decisions and in vaccine regulation.
  • Outlook: If approved, mRNA-1010 could offer a new option for flu prevention, particularly for older adults.